Journal of Inflammation ResearchIan N Foltz,1 Kevin Gaida,2 Helen Y Wong,1 Michael Ng,1 Marijana Busch,1 Jennifer L Liu3 1Amgen Research, Department of Therapeutic Discovery, Amgen Inc., Burnaby, BC, V5A1V7, Canada; 2Research and Development, Amgen Inc., Thousand Oaks, CA, 91320, USA ...
Foltz IN +5 more
doaj
Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]
Int J Technol Assess Health CareHussain A, Fairbairn R, Khan SK.
europepmc +1 more source
Sandoz Inc. v. Amgen Inc.: Removing Barriers to Market Access for Biosimilar Manufacturers [PDF]
, 2019 Koya, Moyosore O.
core +1 more source
Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]
BiologicsRanbhor R, Kulkarni P.
europepmc +1 more source
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]
Pharmaceuticals (Basel)Ponamarev VS.
europepmc +1 more source
Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market [PDF]
Value in Health, 2015 Tuna, E, Kockaya, G
openaire +1 more source
Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]
Clin OphthalmolPloeger CG +3 more
europepmc +1 more source
Understanding the market dynamics of biosimilars
, 2016 Biosimilars represent an attractive market opportunity in the pharmaceutical industry. In order to understand the underlying market dynamics and to identify the success factors of the biosimilars market, a PEST (political, economic, social, technological)
Dassow, J. (Jonas) +3 more
core
Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases. [PDF]
BioDrugsKumar S, Dalbeth N, Gasteiger C.
europepmc +1 more source